Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Next Previous
X
Search
Trial Profile

A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FP-002-Fapon-Biopharma (Primary) ; GLPG 5201 (Primary) ; Cyclophosphamide; Fludarabine; Ibrutinib
  • Indications Chronic lymphocytic leukaemia; Richter's syndrome
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms EUPLAGIA-1
  • Sponsors CellPoint

    • Most Recent Events

    • 05 Nov 2024 According to a Galapagos NV Media Release, results will include additional safety, efficacy, and translational data from 15 patients (cut-off date: February 21, 2024) from this trial will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 7-10 December 2024.
    • 01 Aug 2024 According to a Galapagos NV Media Release, IND filing for Phase 1/2 EUPLAGIA-1 study of GLPG5201 in R/R CLL with or without RT on track for Q4 2024.
    • 04 Apr 2024 According to a Galapagos NV Media Release, data from the study will be presented at the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) to be held in Glasgow, UK, on 14-17 April 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top